CurrentCareSourcePolicy N/A

Hemophilia Factor VIII Products Utilization Management Medical Policy

Defines prior authorization, coverage criteria, and dosing limits for recombinant, extended half-life, standard half-life, and plasma‑derived Factor VIII products used to treat hemophilia A and certain von Willebrand disease indications for CareSource members.

Policy Summary

PayerCareSource

PolicyHemophilia Factor VIII Products Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateFeb 19, 2025

Key ActionObtain prior authorization and ensure the agent is prescribed by or in consultation with a hemophilia specialist; approvals follow the policy dosing and duration limits.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

extended & standard half-lifeproduct classes listed

prior authorizationauthorization requirement

dosing limits includedexplicit IU/kg dosing and frequency

Hemophilia A & VWDconditions covered

Recommended Authorization and Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: FDA‑Approved Indication and Dosing — Hemophilia A

Coverage of listed recombinant and standard half‑life Factor VIII products is recommended when FDA‑approved indications and the dosing/administration constraints below are met.

Specialist-prescribed: Agent is prescribed by or in consultation with a hemophilia specialist

Required for approval; approve for 1 year when criteria met

Indication: Hemophilia A: Requested agent is for treatment of Hemophilia A per FDA‑approved indications

Approve for 1 year when criteria met

Dosing Regimen Group A (Adynovate, Eloctate, Esperoct, Jivi): Choose ONE: i) Routine prophylaxis: approve up to 100 IU/kg IV no more frequently than twice weekly; ii) On-demand treatment and control of bleeding episodes: approve up to 65 IU/kg IV no more frequently than every 8 hours for up to 10 doses per episode; iii) Perioperative management: approve up to 65 IU/kg IV no more frequently than every 6 hours for up to 10 doses per procedure; iv) Immune tolerance therapy as specifiedIU/kg and frequency per policy

Approve selected regimen for 1 year; see policy for exact per‑agent options

Dosing Regimen Group B (Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha): Choose ONE: i) Routine prophylaxis: approve up to 60 IU/kg IV no more frequently than every other day (three or four times weekly); ii) On‑demand treatment and control of bleeding episodes: approve up to 50 IU/kg IV no more frequently than every 6 hours for up to 10 doses per episode; iii) Perioperative management: approve up to 60 IU/kg IV no more frequently than every 6 hours for up to 10 doses per procedure; iv) Immune tolerance therapy: approve up to 200 IU/kg IV no more frequently than once dailyIU/kg and frequency per policy

Approve selected regimen for 1 year; see policy for exact per‑agent limits

inv-02: Plasma‑derived products: Hemophilia A and VWD dosing

Coverage for specific plasma‑derived Factor VIII and vWF/FVIII products is recommended when FDA‑approved indications and the dosing constraints below are met.

Specialist-prescribed: Agent is prescribed by or in consultation with a hemophilia specialist

Required for approval; approve for 1 year when criteria met

Hemofil M and Koate — Hemophilia A dosing: Routine prophylaxis: approve up to 50 IU/kg IV no more frequently than every other day (three or four times weekly); On‑demand/perioperative: approve up to 50 IU/kg IV no more frequently than every 6 hours for up to 10 doses per episode or procedure; Immune tolerance therapy: approve up to 200 IU/kg IV no more frequently than once dailyIU/kg and frequency per policy

Approve for 1 year

Alphanate, Humate‑P, Wilate — Hemophilia A and VWD dosing: Hemophilia A: routine prophylaxis and on‑demand/perioperative dosing up to 50 IU/kg IV no more frequently than every 6 hours for up to 10 doses per episode/procedure; Immune tolerance therapy up to 200 IU/kg IV once daily. VWD: approve up to 80 IU VWF:RCo per kg IV no more frequently than as specified (e.g., every 8–12 hours) for up to 10 days per episode/procedure as measured by VWF:RCo assay

Coverage is recommended only when the requested use and dosing meet the policy's Recommended Authorization Criteria. Coverage is not recommended for circumstances that are not specifically listed in those criteria.

Dosing Limits and Code-Related Details

inv-04: Dosing IU/kg — explicit IU/kg dosing limits and frequencies

Routine prophylaxis (EHL products)Approve up to 100 IU/kg IV no more frequently than twice weekly (Adynovate, Eloctate, Esperoct, Jivi).

On‑demand (EHL)Approve up to 65 IU/kg IV no more frequently than every 8 hours for up to 10 doses per bleeding episode.

Perioperative (EHL)Approve up to 65 IU/kg IV no more frequently than every 6 hours for up to 10 doses per procedure.

Routine prophylaxis (SHL products)Approve up to 60 IU/kg IV no more frequently than every other day (three or four times weekly) for Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, and Xyntha.

On‑demand (SHL)Approve up to 50 IU/kg IV no more frequently than every 6 hours for up to 10 doses per bleeding episode.

Immune tolerance therapyApprove up to 200 IU/kg IV no more frequently than once daily (immune tolerance/induction regimens as specified).

Prior Authorization, Prescribing, and Review Guidance

Prior Authorization

Prior Authorization Required

Prior Authorization is required for medical benefit coverage of the Factor VIII products listed in the policy. Approval is recommended only for members who meet the policy's criteria and dosing. All approvals are provided for the duration noted in the policy. Requests for doses outside the dosing documented in this policy will be considered on a case-by-case basis by a clinician (e.g., Medical Director or Pharmacist).

Applies to: Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil M, Alphanate, Humate-P, Koate, Wilate
Prior Authorization must be obtained before coverage is provided

Documentation Required

Nonstandard Dosing — Case-by-Case Review

Requests for dosing outside the ranges or regimens documented in this policy will be reviewed on a case-by-case basis by a clinician (for example, Medical Director or Pharmacist). Such requests should include supporting clinical justification and relevant documentation.

Prior Authorization

Specialist Prescribing & Prior Authorization

The requested Factor VIII agent must be prescribed by, or in consultation with, a physician who specializes in Hemophilia (a hemophilia specialist). Prior authorization will only be approved when this prescribing requirement is met and documented in the request.

If prescribed in consultation, documentation of specialist involvement (consult note, co-signature, or documented discussion) must be submitted with the PA request
Approvals for FDA‑approved indications (e.g., Hemophilia A) require specialist prescribing/consultation

Denial Risk

Out-of-Criteria Requests Not Recommended

Coverage is not recommended for requests that do not meet the Recommended Authorization Criteria listed in this policy. The criteria will be updated as new published data become available.

Key Terms and Severity Classifications

inv-10: Hemophilia A — definition and severity classifications

DefinitionAn X-linked bleeding disorder caused by deficiency in Factor VIII leading to bleeding into joints and other sites with risk of hemophilic arthropathy.

Severity — SeverePlasma Factor VIII activity < 1% of normal.

Severity — ModeratePlasma Factor VIII activity 1% to 5% of normal.

Severity — MildPlasma Factor VIII activity > 5% to 40% of normal.

inv-11: von Willebrand disease (VWD) — definition and relation to Factor VIII

DefinitionA group of inherited bleeding disorders caused by defects in von Willebrand Factor (vWF) that impair platelet adhesion/aggregation and may accompany reduced Factor VIII levels.

Major subtypesTypes 1, 2 (2A, 2B, 2M, 2N), and 3; type 3 often has very low Factor VIII levels.

Treatment relation to Factor VIIIPlasma‑derived vWF/FVIII concentrates (e.g., Alphanate, Humate‑P, Wilate) are used for replacement; dosing for VWD: approve up to 80 IU VWF:RCo per kg IV no more frequently than specified (up to 10 days per episode/procedure).

OpenPayer

Hemophilia Factor VIII Products Utilization Management Medical Policy

Recommended Authorization and Coverage Criteria

Dosing Limits and Code-Related Details

Prior Authorization, Prescribing, and Review Guidance

Clinical Background

Key Terms and Severity Classifications